Phosphatidylcholine controlled release - Lipid Therapeutics

Drug Profile

Phosphatidylcholine controlled release - Lipid Therapeutics

Alternative Names: LT-02; Phosphatidyl choline; Retarded release phosphatidylcholine

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator University of Heidelberg
  • Developer Dr Falk Pharma; Lipid Therapeutics
  • Class Antiulcers; Cytoprotectives; Glycerophospholipids; Lipids
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ulcerative colitis

Most Recent Events

  • 01 Jul 2016 Phase-III clinical trials in Ulcerative colitis (Adjunctive treatment) in USA (PO) (NCT02849951)
  • 16 Sep 2015 Phosphatidylcholine controlled-release licensed to Nestle Health Science worldwide (excluding Australia and Europe)
  • 31 Oct 2014 Dr Falk Pharma initiates the phase III PROTECT-2 trial in Ulcerative colitis in Germany (NCT02280629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top